Literature DB >> 22023382

Improvement of tardive dyskinesia and dystonia associated with aripiprazole following a switch to quetiapine: case report and review of the literature.

S Ono1, Y Suzuki, M Shindo, T Endo, N Fukui, T Sugai, T Someya.   

Abstract

WHAT IS KNOWN AND
OBJECTIVE: Aripiprazole has a low risk of extrapyramidal symptoms. Switching to aripiprazole has been reported to improve tardive dyskinesia caused by other medications. The authors report a case and review previous reports of dystonia and dyskinesia associated with aripiprazole. CASE
SUMMARY: We present a case of a 22-year-old man with schizophrenia who experienced dyskinesia and dystonia associated with aripiprazole. Switching from olanzapine to aripiprazole resulted in worsening dyskinesia and new onset of dystonia. The patient's dyskinesia and dystonia improved after switching from aripiprazole to quetiapine therapy. WHAT IS NEW AND
CONCLUSION: There were several previous case reports on dyskinesia and dystonia associated with aripiprazole medication. The risk factors for tardive dyskinesia include older age and female sex. However, our case was a male patient who was younger compared with the previous cases and so should have been less at risk for dyskinesia in comparison with the previous cases. The effects of aripiprazole can include tardive movement disorders. Dyskinesia, dystonia and psychotic symptoms were improved with relatively small dose of quetiapine in this case. Whether some second-generation antipsychotics are more effective than others in the treatment of tardive dyskinesia remains unclear.
© 2011 Blackwell Publishing Ltd.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22023382     DOI: 10.1111/j.1365-2710.2011.01290.x

Source DB:  PubMed          Journal:  J Clin Pharm Ther        ISSN: 0269-4727            Impact factor:   2.512


  7 in total

1.  Tardive dyskinesia: therapeutic options for an increasingly common disorder.

Authors:  Leslie J Cloud; Deepti Zutshi; Stewart A Factor
Journal:  Neurotherapeutics       Date:  2014-01       Impact factor: 7.620

Review 2.  Tardive Dyskinesia Associated with Atypical Antipsychotics: Prevalence, Mechanisms and Management Strategies.

Authors:  Katharina Stegmayer; Sebastian Walther; Peter van Harten
Journal:  CNS Drugs       Date:  2018-02       Impact factor: 5.749

3.  Late-onset Quetiapine-related Tardive Dyskinesia Side Effects in a Patient with Psychotic Depression.

Authors:  Yi-Cheng Hou; Chien-Han Lai
Journal:  Clin Psychopharmacol Neurosci       Date:  2014-08-12       Impact factor: 2.582

4.  Opposite effects of typical and atypical anti-psychotic drugs on sensitized dopamine receptors: sub-chronic low dose Olanzapine exposure reverses sensitization but a similar regimen of low dose haloperidol potentiates sensitization effects.

Authors:  Flávia Regina Cruz Dias; João Marcos de Mello Bastos; Maria de Fátima Dos Santos Sampaio; Robert J Carey; Marinete Pinheiro Carrera
Journal:  Psychopharmacology (Berl)       Date:  2013-07-12       Impact factor: 4.530

5.  Role of aripiprazole in treatment-resistant schizophrenia.

Authors:  Nilufar Mossaheb; Rainer M Kaufmann
Journal:  Neuropsychiatr Dis Treat       Date:  2012-05-29       Impact factor: 2.570

6.  Acute Dystonia Following a Switch in Treatment from Atomoxetine to Low-dose Aripiprazole.

Authors:  Ömer Başay; Burge Kabukcu Basay; Önder Öztürk; Zeki Yüncü
Journal:  Clin Psychopharmacol Neurosci       Date:  2016-05-31       Impact factor: 2.582

Review 7.  Safety, tolerability, and risks associated with first- and second-generation antipsychotics: a state-of-the-art clinical review.

Authors:  Marco Solmi; Andrea Murru; Isabella Pacchiarotti; Juan Undurraga; Nicola Veronese; Michele Fornaro; Brendon Stubbs; Francesco Monaco; Eduard Vieta; Mary V Seeman; Christoph U Correll; André F Carvalho
Journal:  Ther Clin Risk Manag       Date:  2017-06-29       Impact factor: 2.423

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.